Andrew Lin

1.6k total citations
38 papers, 541 citations indexed

About

Andrew Lin is a scholar working on Genetics, Endocrinology, Diabetes and Metabolism and Epidemiology. According to data from OpenAlex, Andrew Lin has authored 38 papers receiving a total of 541 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Genetics, 14 papers in Endocrinology, Diabetes and Metabolism and 12 papers in Epidemiology. Recurrent topics in Andrew Lin's work include Glioma Diagnosis and Treatment (22 papers), Pituitary Gland Disorders and Treatments (14 papers) and Brain Metastases and Treatment (8 papers). Andrew Lin is often cited by papers focused on Glioma Diagnosis and Treatment (22 papers), Pituitary Gland Disorders and Treatments (14 papers) and Brain Metastases and Treatment (8 papers). Andrew Lin collaborates with scholars based in United States, Germany and Canada. Andrew Lin's co-authors include David H. Gutmann, Viviane Tabar, Eliza B. Geer, Robert J. Young, Lisa M. DeAngelis, Jonathan T. Yang, Marc K. Rosenblum, Marc A. Cohen, John Cuaron and Philip Jonsson and has published in prestigious journals such as Journal of Clinical Oncology, Gastroenterology and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Andrew Lin

34 papers receiving 534 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Andrew Lin United States 15 292 226 164 105 100 38 541
Yukui Wei China 10 220 0.8× 79 0.3× 114 0.7× 68 0.6× 65 0.7× 18 408
Benjamin Liechty United States 12 211 0.7× 62 0.3× 235 1.4× 262 2.5× 88 0.9× 40 576
Dabiao Zhou China 11 177 0.6× 74 0.3× 81 0.5× 78 0.7× 58 0.6× 33 356
Vaishali Suri India 12 125 0.4× 67 0.3× 88 0.5× 65 0.6× 93 0.9× 41 401
Alessandro Villa Italy 15 213 0.7× 276 1.2× 295 1.8× 99 0.9× 288 2.9× 32 674
Francesca Ambrosi Italy 15 89 0.3× 196 0.9× 81 0.5× 21 0.2× 183 1.8× 58 499
Mantana Dhanachai Thailand 11 115 0.4× 33 0.1× 136 0.8× 132 1.3× 56 0.6× 30 374
Sanjay Dhawan United States 12 154 0.5× 26 0.1× 68 0.4× 98 0.9× 44 0.4× 37 387
Mariko Kurokawa Japan 13 134 0.5× 22 0.1× 57 0.3× 98 0.9× 91 0.9× 73 509
I. Niedermayer Germany 12 82 0.3× 64 0.3× 341 2.1× 274 2.6× 159 1.6× 23 500

Countries citing papers authored by Andrew Lin

Since Specialization
Citations

This map shows the geographic impact of Andrew Lin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew Lin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew Lin more than expected).

Fields of papers citing papers by Andrew Lin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew Lin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew Lin. The network helps show where Andrew Lin may publish in the future.

Co-authorship network of co-authors of Andrew Lin

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew Lin. A scholar is included among the top collaborators of Andrew Lin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew Lin. Andrew Lin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Raverot, Gérald, Pia Burman, Ana Paula Abreu, et al.. (2025). Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas. European Journal of Endocrinology. 192(6). G1–G34. 3 indexed citations
2.
Reiner, Anne S., et al.. (2025). Prospective Assessment of Mood and Quality of Life in Cushing Syndrome Before and After Biochemical Control. The Journal of Clinical Endocrinology & Metabolism.
3.
Lin, Andrew, Vasilisa A. Rudneva, Nazanin Majd, et al.. (2025). Immune Checkpoint Inhibitor Therapy for Aggressive Pituitary Neuroendocrine Tumors. The Journal of Clinical Endocrinology & Metabolism. 110(11). 3066–3073. 5 indexed citations
4.
Lin, I‐Hsin, et al.. (2024). Different patient versus provider perspectives on living with Cushing’s disease. Pituitary. 27(2). 141–150. 3 indexed citations
5.
Lin, Andrew, Eliza B. Geer, Gabrielle Page‐Wilson, et al.. (2023). The treatment of aggressive prolactinomas with everolimus. Pituitary. 26(4). 474–481. 7 indexed citations
6.
Lin, Andrew, Viviane Tabar, Robert J. Young, & Eliza B. Geer. (2023). Dabrafenib as a diagnostic and therapeutic strategy for the non-surgical management of papillary craniopharyngioma. Pituitary. 26(4). 482–487. 9 indexed citations
7.
Rana, Satshil, Anne S. Reiner, Andrew Lin, et al.. (2023). Leptomeningeal disease in histone-mutant gliomas. Neuro-Oncology Advances. 5(1). vdad068–vdad068. 3 indexed citations
8.
Schaff, Lauren, Andrew Lin, Subhiksha Nandakumar, et al.. (2022). Combination Olaparib and Temozolomide for the Treatment of Glioma. Neurology. 99(17). 750–755. 7 indexed citations
9.
Lin, Andrew, Alexandra Miller, Igor T. Gavrilovic, et al.. (2022). Concurrent Olaparib and Temozolomide for Recurrent Glioma (P5-9.005). Neurology. 98(18_supplement).
10.
Lin, Andrew, Viviane Tabar, Robert J. Young, et al.. (2021). Synergism of Checkpoint Inhibitors and Peptide Receptor Radionuclide Therapy in the Treatment of Pituitary Carcinoma. Journal of the Endocrine Society. 5(10). bvab133–bvab133. 30 indexed citations
11.
Hagen, Matthew, Karl C. Golnik, Abdelkader Mahammedi, et al.. (2021). BRMP-03. Pituitary carcinoma: a case of dramatic response to immunotherapy (ipilimumab + nivolumab) after failure with temozolomide. Neuro-Oncology. 23(Supplement_6). vi223–vi223.
12.
Lin, Andrew, Mark T.A. Donoghue, Sharon L. Wardlaw, et al.. (2020). Approach to the Treatment of a Patient with an Aggressive Pituitary Tumor. The Journal of Clinical Endocrinology & Metabolism. 105(12). 3807–3820. 15 indexed citations
13.
Imber, Brandon S., Andrew Lin, Zhigang Zhang, et al.. (2019). Comparison of Radiographic Approaches to Assess Treatment Response in Pituitary Adenomas: Is RECIST or RANO Good Enough?. Journal of the Endocrine Society. 3(9). 1693–1706. 22 indexed citations
14.
Schaff, Lauren, Dongyao Yan, Sheeno Thyparambil, et al.. (2019). Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival. Journal of Neuro-Oncology. 146(1). 163–170. 26 indexed citations
15.
Lockney, Natalie A., Diana G. Wang, Xin Pei, et al.. (2018). Phosphatidylinositol-3-Kinase Mutations Are Associated With Increased Local Failure in Brain Metastases Treated With Radiation. International Journal of Radiation Oncology*Biology*Physics. 101(4). 833–844. 3 indexed citations
16.
Lin, Andrew & David H. Gutmann. (2013). Advances in the treatment of neurofibromatosis-associated tumours. Nature Reviews Clinical Oncology. 10(11). 616–624. 54 indexed citations
17.
Lin, Andrew, Jingxia Liu, J.G. Evans, et al.. (2013). Codeletions at 1p and 19q predict a lower risk of pseudoprogression in oligodendrogliomas and mixed oligoastrocytomas. Neuro-Oncology. 16(1). 123–130. 16 indexed citations
18.
Lin, Andrew & Joseph E. Safdieh. (2010). The Evaluation and Management of Bacterial Meningitis. The Neurologist. 16(3). 143–151. 11 indexed citations
19.
Weber, H. Christian, Deborah J. Marsh, Irina A. Lubensky, Andrew Lin, & Charis Eng. (1998). Germline PTEN/MMAC1/TEP1 mutations and association with gastrointestinal manifestations in Cowden disease. Gastroenterology. 114. A702–A702. 9 indexed citations
20.
Tien, Hui‐Ju, C. M. Suchindran, Virginia P. Sybert, et al.. (1994). Tracheolaryngeal stenosis and inherited EB (EB): Determination of differences in time of onset as assessed by lifetable analysis technique. Journal of Investigative Dermatology. 103(6). 848. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yukui Wei Breakdown of academic impact, for papers by Benjamin Liechty Breakdown of academic impact, for papers by Dabiao Zhou Breakdown of academic impact, for papers by Vaishali Suri Breakdown of academic impact, for papers by Alessandro Villa Breakdown of academic impact, for papers by Francesca Ambrosi Breakdown of academic impact, for papers by Mantana Dhanachai Breakdown of academic impact, for papers by Sanjay Dhawan Breakdown of academic impact, for papers by Mariko Kurokawa Breakdown of academic impact, for papers by I. Niedermayer
Rankless by CCL
2026